One in 35 myocardial injury
Dr. John Campbell
2.83M subscribers
1,228,158 views Jul 26, 2023
Myocardial Injury after COVID-19 mRNA-1273 Booster Vaccination
https://onlinelibrary.wiley.com/doi/e…
Department of Cardiology and Cardiovascular Research Institute Basel
(ESC Heart Failure, open-access journal of the Heart Failure Association of the European Society of Cardiology)
Prospective active surveillance study
(Not a retrospective passive surveillance study)
Industry independent, instigated by the investigators
Aims
Incidence and potential mechanisms of oligosymptomatic myocardial injury,
following COVID-19 mRNA booster vaccination.
Safety net for those already boosted,
screening and prevention of complications
Methods and Results
December 2021 to February 2022
Hospital employees scheduled to undergo mRNA-1273 booster vaccination,
assessed for mRNA-1273 vaccination-associated myocardial injury,
defined as acute dynamic increase in high-sensitivity cardiac troponin T (hs-cTnT) concentration,
above the sex-specific upper-limit of normal on day 3 (48-96h)
after vaccination without evidence of an alternative cause.
777 participants
Median age 37 years, 69.5% women
40 participants (5.1%) had elevated high-sensitivity cardiac troponin T concentration on day 3
(Taken as above the 99th percentile for age and sex)
mRNA-1273 vaccine-associated myocardial injury was adjudicated in 22 participants (2.8%).
One in 35 recipients (2.8%) had vaccine-associated myocardial injury
Of the 777, 2 women had chest pain
Of these 22 cases with mRNA-1273 vaccine-associated myocardial injury
Twenty cases occurred in women
Two in men
Hs-cTnT-elevations were mild and only temporary.
No patient had ECG- changes,
none developed major adverse cardiac events within 30 days
In the overall booster cohort
hs-cTnT concentrations, on day 3
Median 5 ng/L, IQR, 4-6
Matched controls (n=777), 3 ng/L IQR, 3-5
Significantly higher p less than 0.001
(If elevated on day3, given warning, investigations and advice)
No MACE (major adverse cardiac events) within 30 days
Cases had comparable systemic reactogenicity
Concentrations of cytokines and cytokine antagonists were markers quantifying systemic inflammation
Lower concentrations
GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) induces the development of monocytes, neutrophils, eosinophils, and myeloid and dermal dendritic cells.
IFN- λ1(IL-29) a group of anti-viral cytokines, that consists of four IFN-λ molecules
Conclusion
mRNA-1273 vaccine-associated myocardial injury was more common than previously thought,
being mild and transient,
and more frequent in women versus men.
The possible protective role of IFN-λ1(IL-29) and GM-CSF warrant further studies.
Similar Pfizer studies
A prospective study on myocardial injury after BNT162b2 mRNA COVID-19 fourth dose vaccination in healthy persons
https://pubmed.ncbi.nlm.nih.gov/36097…
A prospective study on myocardial injury after BNT162b2 mRNA COVID-19 fourth dose vaccination in healthy persons
https://onlinelibrary.wiley.com/doi/1…\
NZ Pfizer add
https://www.everydayheroestakeaction….
New hope children centre
https://www.newhopeuplands.org
If you would like to support the work in Africa, donations are welcome using the PayPal link below. 100% of funds go directly to Africa. Thank you.
https://www.paypal.com/donate/?hosted…
Dr. John Campbell
2.83M subscribers
myocardial injuryincidence after COVID-19 mRNA-1273booster vaccination
Hospital employees scheduled to undergo mRNA-1273 booster vaccination were assessed for mRNA-1273vaccination-associated myocardial injury,
increase in high-sensitivity cardiac troponin T(hs-cTnT) concentration above the sex-specific upper limit of normal on day 3 (48–96 h) after vaccination withoutevidence of an alternative cause
40/777, 5.% had elevated hs-cTnT concentration on day 3
mRNA-1273 vaccine-associated myocardialinjury was adjudicated in 22 participants (2.8%
Twenty cases occurred in women (3.7%[95% CI 2.3–5.7%]), two in men (0.8% [95% CI 0.1–3.0%])
Hs-cTnT elevations were mild and only temporary.
No patient had electrocardiographic changes, and none developed major adverse cardiac events within 30 day
. In the overall booster cohort, hs-cTnT concentrations (day 3; median 5, interquartilerange [IQR] 4–6 ng/L) were significantly higher compared to matched controls (n=777, median 3 [IQR 3–5]ng/L,p<0.001).
possible protective role of IFN-λ1(IL-29) and GM-CSFwarrant further studies.
